RU2014130743A - Таблетки и средства с сухим покрытием - Google Patents

Таблетки и средства с сухим покрытием Download PDF

Info

Publication number: RU2014130743A
Authority: RU; Russia
Prior art keywords: tablet; sodium; tablet according; disintegrant; component selected
Prior art date: 2011-12-26

Application number

RU2014130743A

Other languages

English (en)

Russian (ru)

Inventor

Масаки АНДО

Таканори ИТИХАСИ

Саяка КОДЗИМА

Масато САКУРАИ

Рина ТАНАКА

Original Assignee

Новартис Аг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-26

Filing date

2012-12-21

Publication date

2016-02-20

2011-12-26 Priority claimed from JP2011284027A external-priority patent/JP2013133291A/ja

2011-12-26 Priority claimed from JP2011284036A external-priority patent/JP2013133292A/ja

2012-12-21 Application filed by Новартис Аг filed Critical Новартис Аг

2016-02-20 Publication of RU2014130743A publication Critical patent/RU2014130743A/ru

Links

239000003826 tablet Substances 0.000 claims abstract 25
239000007884 disintegrant Substances 0.000 claims abstract 12
239000000314 lubricant Substances 0.000 claims abstract 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
150000003839 salts Chemical class 0.000 claims abstract 9
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract 8
235000012239 silicon dioxide Nutrition 0.000 claims abstract 8
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract 6
239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract 6
239000011734 sodium Substances 0.000 claims abstract 6
229910052708 sodium Inorganic materials 0.000 claims abstract 6
238000006467 substitution reaction Methods 0.000 claims abstract 6
239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract 5
229920002472 Starch Polymers 0.000 claims abstract 5
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims abstract 5
239000008107 starch Substances 0.000 claims abstract 5
229940032147 starch Drugs 0.000 claims abstract 5
235000019698 starch Nutrition 0.000 claims abstract 5
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract 5
229960004699 valsartan Drugs 0.000 claims abstract 5
229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract 4
229920002785 Croscarmellose sodium Polymers 0.000 claims abstract 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 4
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims abstract 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract 4
235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract 4
229950008138 carmellose Drugs 0.000 claims abstract 4
229960001681 croscarmellose sodium Drugs 0.000 claims abstract 4
229960000913 crospovidone Drugs 0.000 claims abstract 4
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract 4
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract 4
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract 4
210000003296 saliva Anatomy 0.000 claims abstract 4
229940080313 sodium starch Drugs 0.000 claims abstract 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract 3
239000000378 calcium silicate Substances 0.000 claims abstract 3
229910052918 calcium silicate Inorganic materials 0.000 claims abstract 3
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims abstract 3
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims abstract 3
229940083542 sodium Drugs 0.000 claims abstract 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 2
229920002907 Guar gum Polymers 0.000 claims abstract 2
229920000881 Modified starch Polymers 0.000 claims abstract 2
239000011575 calcium Substances 0.000 claims abstract 2
229910052791 calcium Inorganic materials 0.000 claims abstract 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract 2
239000001913 cellulose Substances 0.000 claims abstract 2
229920002678 cellulose Polymers 0.000 claims abstract 2
239000000665 guar gum Substances 0.000 claims abstract 2
235000010417 guar gum Nutrition 0.000 claims abstract 2
229960002154 guar gum Drugs 0.000 claims abstract 2
229940071676 hydroxypropylcellulose Drugs 0.000 claims abstract 2
239000006191 orally-disintegrating tablet Substances 0.000 claims abstract 2
235000015424 sodium Nutrition 0.000 claims abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
235000003599 food sweetener Nutrition 0.000 claims 7
239000003765 sweetening agent Substances 0.000 claims 7
239000011248 coating agent Substances 0.000 claims 6
235000019359 magnesium stearate Nutrition 0.000 claims 4
-1 sodium starch Substances 0.000 claims 3
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims 2
UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 2
108010011485 Aspartame Proteins 0.000 claims 2
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
239000004376 Sucralose Substances 0.000 claims 2
229930006000 Sucrose Natural products 0.000 claims 2
229960004601 aliskiren Drugs 0.000 claims 2
HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims 2
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims 2
229940063655 aluminum stearate Drugs 0.000 claims 2
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 2
229960000528 amlodipine Drugs 0.000 claims 2
239000000605 aspartame Substances 0.000 claims 2
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 2
235000010357 aspartame Nutrition 0.000 claims 2
229960003438 aspartame Drugs 0.000 claims 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
239000008116 calcium stearate Substances 0.000 claims 2
235000013539 calcium stearate Nutrition 0.000 claims 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 2
239000008199 coating composition Substances 0.000 claims 2
235000014113 dietary fatty acids Nutrition 0.000 claims 2
239000000194 fatty acid Substances 0.000 claims 2
229930195729 fatty acid Natural products 0.000 claims 2
229960002003 hydrochlorothiazide Drugs 0.000 claims 2
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 2
239000000347 magnesium hydroxide Substances 0.000 claims 2
229910001862 magnesium hydroxide Inorganic materials 0.000 claims 2
239000000395 magnesium oxide Substances 0.000 claims 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 2
239000003002 pH adjusting agent Substances 0.000 claims 2
229920001223 polyethylene glycol Polymers 0.000 claims 2
235000019204 saccharin Nutrition 0.000 claims 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 2
229940081974 saccharin Drugs 0.000 claims 2
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 2
235000019408 sucralose Nutrition 0.000 claims 2
BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 2
239000005720 sucrose Substances 0.000 claims 2
239000000454 talc Substances 0.000 claims 2
229910052623 talc Inorganic materials 0.000 claims 2
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 1
BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 claims 1
244000228451 Stevia rebaudiana Species 0.000 claims 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
230000002378 acidificating effect Effects 0.000 claims 1
229960004543 anhydrous citric acid Drugs 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
150000004665 fatty acids Chemical class 0.000 claims 1
HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims 1
235000018342 monosodium citrate Nutrition 0.000 claims 1
239000002524 monosodium citrate Substances 0.000 claims 1
HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims 1
239000000892 thaumatin Substances 0.000 claims 1
235000010436 thaumatin Nutrition 0.000 claims 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

RU2014130743A 2011-12-26 2012-12-21 Таблетки и средства с сухим покрытием RU2014130743A (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2011-284036		2011-12-26
JP2011284027A JP2013133291A (ja)	2011-12-26	2011-12-26	錠剤
JP2011284036A JP2013133292A (ja)	2011-12-26	2011-12-26	有核剤
JP2011-284027		2011-12-26
PCT/EP2012/076794 WO2013098268A2 (fr)	2011-12-26	2012-12-21	Comprimés et agents enrobés à sec

Publications (1)

Publication Number	Publication Date
RU2014130743A true RU2014130743A (ru)	2016-02-20

Family

ID=47436010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2014130743A RU2014130743A (ru)	2011-12-26	2012-12-21	Таблетки и средства с сухим покрытием

Country Status (8)

Country	Link
EP (1)	EP2797580A2 (fr)
JP (1)	JP2015504878A (fr)
KR (1)	KR20140108652A (fr)
AU (1)	AU2012360935A1 (fr)
BR (1)	BR112014015620A8 (fr)
MX (1)	MX2014007933A (fr)
RU (1)	RU2014130743A (fr)
WO (1)	WO2013098268A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI690333B (zh) *	2015-06-29	2020-04-11	日商大賽璐股份有限公司	易服用性固態製劑（有核錠）之製造方法及易服用性固態製劑
EP4243633A1 (fr) *	2020-11-13	2023-09-20	Sila S.P.A.	Composé dispersible par voie orale contenant un ester ou un sel d'acide n-butyrique et procédé de production
CN112826806A (zh) *	2021-01-20	2021-05-25	海南皇隆制药股份有限公司	一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) *	2021-01-20	2021-05-18	海南皇隆制药股份有限公司	一种缬沙坦分散片制备方法和缬沙坦分散片
JP7698962B2 (ja) *	2021-03-19	2025-06-26	三栄源エフ・エフ・アイ株式会社	不快風味のマスキング方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122010000024I1 (de)	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
JP3069458B2 (ja)	1992-01-29	2000-07-24	武田薬品工業株式会社	口腔内崩壊型錠剤およびその製造法
NZ278678A (en)	1994-01-31	1998-03-25	Yamanouchi Pharma Co Ltd	Compressed moulded tablet with quick disintegration/dissolution in the mouth, mixture of low and high moldable saccharides as carriers
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
CA2311734C (fr) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Forme pharmaceutique orale a dissolution ultra-rapide
WO2003028706A1 (fr) *	2001-09-28	2003-04-10	Sanwa Kagaku Kenkyusho Co.,Ltd	Double comprime a desintegration rapide
WO2007052307A2 (fr) *	2005-10-31	2007-05-10	Lupin Limited	Formes posologiques solides orales stables de valsartan
AR061627A1 (es) *	2006-06-27	2008-09-10	Novartis Ag	Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
PE20090654A1 (es) *	2007-09-28	2009-06-27	Novartis Ag	Formulaciones galenicas que contienen alisquireno y valsartan
JP2009114113A (ja) *	2007-11-06	2009-05-28	Nipro Corp	口腔内崩壊錠及びその製造方法
RU2488393C2 (ru) *	2007-11-12	2013-07-27	Новартис Аг	Жидкие композиции, включающие валсартан
JP5296456B2 (ja) *	2008-08-26	2013-09-25	大日本住友製薬株式会社	溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2010065489A1 (fr) *	2008-12-02	2010-06-10	Sciele Pharma, Inc.	Composition d’agoniste alpha2-adrénergique et d’antagoniste de récepteur d’angiotensine ii
WO2010146551A2 (fr) *	2009-06-16	2010-12-23	Ranbaxy Laboratories Limited	Compositions à désintégration orale comprenant des agents anti-hypertensifs
JP2013023463A (ja) *	2011-07-20	2013-02-04	Ohara Yakuhin Kogyo Kk	生理活性物質含有粒子の製造方法

2012
- 2012-12-21 JP JP2014548092A patent/JP2015504878A/ja active Pending
- 2012-12-21 RU RU2014130743A patent/RU2014130743A/ru not_active Application Discontinuation
- 2012-12-21 MX MX2014007933A patent/MX2014007933A/es unknown
- 2012-12-21 EP EP12806509.1A patent/EP2797580A2/fr not_active Withdrawn
- 2012-12-21 WO PCT/EP2012/076794 patent/WO2013098268A2/fr not_active Ceased
- 2012-12-21 BR BR112014015620A patent/BR112014015620A8/pt not_active IP Right Cessation
- 2012-12-21 AU AU2012360935A patent/AU2012360935A1/en not_active Abandoned
- 2012-12-21 KR KR1020147017155A patent/KR20140108652A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
MX2014007933A (es)	2014-07-30
BR112014015620A8 (pt)	2017-07-04
WO2013098268A3 (fr)	2013-08-22
BR112014015620A2 (pt)	2017-06-13
AU2012360935A1 (en)	2014-07-17
EP2797580A2 (fr)	2014-11-05
KR20140108652A (ko)	2014-09-12
JP2015504878A (ja)	2015-02-16
WO2013098268A2 (fr)	2013-07-04

Publication	Publication Date	Title
RU2014130743A (ru)	2016-02-20	Таблетки и средства с сухим покрытием
AR069031A1 (es)	2009-12-23	Composicion
RU2005115855A (ru)	2006-01-20	Композиция трамадола продлонгированного высвобождением с 24-часовым действием
JO2641B1 (en)	2012-06-17	Pharmaceutical compounds containing calcium rosofastatin
EP2444072A3 (fr)	2014-05-07	Formes galéniques de film non mucoadhésifs
JP2005538104A5 (fr)	2008-07-17
HRP20140780T4 (hr)	2021-08-06	Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze
UA116334C2 (uk)	2018-03-12	Тверді форми дозування бендамустину
WO2008129517A3 (fr)	2009-05-07	Composition pharmaceutique à libération prolongée stabilisée de rabéprazole
BRPI0817275A2 (pt)	2015-06-16	Combinação farmacêutica de alisquireno e valsartana
FI4101454T3 (fi)	2024-06-10	Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon
JP2009541409A5 (fr)	2010-06-17
NO20066076L (no)	2007-02-14	Tyggbar, sugbar og svelgbar tablett som inneholder en kalsium-inneholdende forbindelse som en aktiv substans
JP2007197357A5 (fr)	2009-03-12
MY146988A (en)	2012-10-15	Fexofenadine suspension formulation
JP2011512394A5 (fr)	2013-08-01
EA201170101A1 (ru)	2011-08-30	Фармацевтические композиции роувастатина кальция
ES2534312T3 (es)	2015-04-21	Procedimiento de estabilización de un suplemento dietético que comprende glucosamina
RU2008139625A (ru)	2010-04-20	Композиции и способы лечения ревматоидного артрита
WO2006033505A8 (fr)	2006-09-14	Sels derives de cholate de paroxetine ou d'acide cholique, et composition comportant de la paroxetine et de l'acide cholique ou des derives de l'acide cholique
ATE517612T1 (de)	2011-08-15	Rabeprazol-formulierung
WO2009000909A8 (fr)	2009-02-12	Sels de périndopril
WO2005051349A3 (fr)	2005-07-28	Compositions pharmaceutiques de mirtazapine
EA200600173A1 (ru)	2006-08-25	Диспергируемая во рту фармацевтическая композиция антитромботического соединения
WO2020101597A3 (fr)	2020-07-02	Compositions de capsules comprenant des inhibiteurs de la tyrosine-kinase

Legal Events

Date	Code	Title	Description
2017-05-20	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20170516